SCHEMBL4317606

SCHEMBL4317606

CCN(CC)CCNCc1ccc(/C=C/c2n[nH]c3ccccc23)c(NC(=O)c2sccc2C)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 4/20 0.58
▸ AURKB Q96GD4 3/20 0.58
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ CASP3 P42574 1/20 0.36
▸ SENP8 Q96LD8 1/20 0.36
▸ SENP7 Q9BQF6 1/20 0.36
▸ SENP6 Q9GZR1 1/20 0.36
▸ KDR P35968 4/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ PARP1 P09874 1/20 0.35
▸ FGFR1 P11362 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4317617 1.00 AURKA (0.58) AURKAAURKBNPC1RAB9ACASP3
SCHEMBL4313397 0.89 AURKA (0.57) AURKAAURKBNPC1RAB9ACASP3
SCHEMBL4313384 0.89 AURKA (0.57) AURKAAURKBNPC1RAB9ACASP3
SCHEMBL14988985 0.88 AURKA (0.46) AURKAAURKBKDRKMT2ASMN1; SMN2
SCHEMBL4308987 0.88 AURKA (0.53) AURKAAURKBNPC1RAB9AKDR
SCHEMBL4308998 0.88 AURKA (0.53) AURKAAURKBNPC1RAB9AKDR
SCHEMBL4321138 0.87 AURKA (0.63) AURKAAURKBNPC1RAB9ACASP3
SCHEMBL4321146 0.87 AURKA (0.63) AURKAAURKBNPC1RAB9ACASP3
Hydrochloric Acid SCHEMBL4327292 0.87 AURKA (0.52) AURKAAURKBNPC1RAB9AKDR
Hydrochloric Acid SCHEMBL4327306 0.87 AURKA (0.52) AURKAAURKBNPC1RAB9AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 — — EP claimed
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 — — EP disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885NPC1 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback